Compare VFC & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VFC | PCVX |
|---|---|---|
| Founded | 1899 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4B | 6.1B |
| IPO Year | 1994 | 2020 |
| Metric | VFC | PCVX |
|---|---|---|
| Price | $17.21 | $59.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 7 |
| Target Price | $17.56 | ★ $98.33 |
| AVG Volume (30 Days) | ★ 5.3M | 1.1M |
| Earning Date | 04-28-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.72 | N/A |
| EPS | ★ 0.95 | N/A |
| Revenue | ★ $10,488,556,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.06 | N/A |
| P/E Ratio | $18.26 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.41 | $28.09 |
| 52 Week High | $21.92 | $76.61 |
| Indicator | VFC | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 30.00 | 57.17 |
| Support Level | $13.83 | $42.30 |
| Resistance Level | $20.40 | $65.00 |
| Average True Range (ATR) | 0.86 | 3.19 |
| MACD | -0.35 | -0.35 |
| Stochastic Oscillator | 20.12 | 53.80 |
VF designs, produces, and distributes branded apparel, footwear, and accessories. Its apparel categories are active, outdoor, and work. Its portfolio of 10 brands includes Vans, The North Face, Timberland, and Altra. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. Tracing its roots to 1899, the company has evolved through many brand acquisitions and dispositions.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.